Company news
Spruce Biosciences, Inc. (NASDAQ:SPRB) news
Spruce Biosciences, Inc. news releases on 6ix. Latest, Jan 4, 2024: Spruce Biosciences Provides Clinical Program Updates and Outlook for 2024
Press releases — page 2
Spruce Biosciences Provides Clinical Program Updates and Outlook for 2024
January 3, 2024
Spruce Biosciences Reports Third Quarter 2023 Financial Results and Provides Corporate Updates
November 12, 2023
Spruce Biosciences Completes Target Enrollment of CAHmelia-203 Study in Adult Classic Congenital Adrenal Hyperplasia
October 17, 2023
Spruce Biosciences Reports Second Quarter 2023 Financial Results and Provides Corporate Updates
August 13, 2023
Spruce Biosciences Announces Acceptance of Abstract for Presentation at the Annual Meeting of the Endocrine Society (ENDO 2023)
June 11, 2023
Spruce Biosciences Appoints Percival Barretto-Ko to Board of Directors
May 24, 2023
Spruce Biosciences Reports First Quarter 2023 Financial Results and Provides Corporate Updates
May 14, 2023
Spruce Biosciences Reports Full Year 2022 Financial Results and Provides Corporate Updates
March 15, 2023
Spruce Biosciences Announces $53.6 Million Private Placement Financing
February 8, 2023
Spruce Biosciences Provides Clinical Program Updates and Outlines Anticipated Milestones for 2023
January 8, 2023
Spruce Biosciences and Kaken Pharmaceutical Announce Strategic Partnership and Exclusive Licensing Agreement to Develop and Commercialize Tildacerfont for CAH in Japan
January 4, 2023
Spruce Biosciences Reports Third Quarter 2022 Financial Results and Provides Corporate Updates
November 9, 2022
Spruce Biosciences Reports Second Quarter 2022 Financial Results and Provides Corporate Update
August 9, 2022
Spruce Biosciences Announces Acceptance of Abstract for Presentation at ENDO 2022 Annual Conference
May 30, 2022
Spruce Biosciences Reports First Quarter 2022 Financial Results and Provides Corporate Update
May 10, 2022
Spruce Biosciences Appoints Libbie Mansell, Ph.D., M.B.A., R.A.C., as Chief Regulatory and Quality Officer
April 10, 2022
Spruce Biosciences Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Updates
March 13, 2022
Spruce Biosciences Appoints Will Charlton, M.D., M.A.S., as Chief Medical Officer
March 13, 2022
Spruce Biosciences Provides Clinical Program Updates and Outlook for 2022
January 23, 2022
Spruce Biosciences Appoints Javier Szwarcberg, M.D., MPH as Chief Executive Officer
January 4, 2022
Spruce Biosciences Appoints Mike Grey as Interim CEO
November 14, 2021
Spruce Biosciences Announces Pediatric Classic CAH Program Details During Virtual R&D Day
August 24, 2021
Spruce Biosciences to Host Virtual R&D Day on August 25, 2021
August 10, 2021
Spruce Biosciences Reports Second Quarter 2021 Financial Results and Provides Corporate Updates
August 9, 2021
Spruce Biosciences Appoints Renowned Drug Developer Kirk Ways, M.D., Ph.D. to Board of Directors
June 23, 2021
Spruce Biosciences Announces Publication of Phase 2 Results for Tildacerfont in Journal of Clinical Endocrinology and Metabolism
June 20, 2021
Spruce Biosciences Reports First Quarter 2021 Financial Results and Provides Corporate Updates
May 11, 2021
Spruce Biosciences Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Recent Corporate Updates
March 21, 2021
Spruce Biosciences Provides Corporate Update and Outlines Milestones for 2021
January 5, 2021
Spruce Biosciences Reports Third Quarter 2020 Financial Results and Provides Corporate Update
November 17, 2020
Spruce Biosciences Announces Closing of Upsized Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
October 13, 2020